Patent US5601842A successfully refreshed from Google Patents.
US5601842A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release drug formulation containing a tramadol salt
Assignee: Grünenthal GmbH
•
Filing: 1996-01-16
•
Granted: 1997-02-11
•
Expires: 2016-01-16
Abstract
Abstract A drug formulation of tramadol or a tramadol salt in orally administrable tablet form containing at least one pharmaceutically acceptable matrixing agent is disclosed from which a non-moisture sensitive, physiologically acceptable tramadol salt is sustained released.
Inventors
- 👤 Johannes H. A. Bartholomaeus
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 14:30
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2054; A61K9/28; A61K9/2806; A61K9/2833; A61K9/2853; A61K9/286; A61K9/2866; A61P; A61P25/00; A61P25/04; A61P29/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
98 words
A drug formulation in tablet form with sustained release of an active ingredient, said drug formulation consisting essentially of from 10 to 85% by weight of non-moisture sensitive, physiologically acceptable tramadol hydrochloride as said active ingredient; from 10 to 40% by weight of at least one pharmaceutically acceptable matrixing agent selected from the group consisting of methylhydroxypropylcelluloses, hydroxyethylcelluloses and hydroxypropylcelluloses having a viscosity between 3,000 and 150,000 mPas in a 2% by weight aqueous solution at 20° C., and from 0 to 80% by weight of conventional excipients selected from the group consisting of fillers, lubricants, and glidants.
Claim 2
Dependent Claim
98 words
A drug formulation in tablet form with sustained release of an active ingredient, said drug formulation consisting essentially of from 10 to 85% by weight of non-moisture sensitive, physiologically acceptable tramadol hydrochloride as said active ingredient; from 10 to 40% by weight of at least one pharmaceutically acceptable matrixing agent selected from the group consisting of methylhydroxypropylcelluloses, hydroxyethylcelluloses and hydroxypropylcelluloses having a viscosity between 3,000 and 150,000 mPas in a 2% by weight aqueous solution at 20° C., and from 0 to 80% by weight of conventional excipients selected from the group consisting of fillers, lubricants, and glidants.
Claim 3
Dependent Claim
29 words
A drug formulation according to claim 1, wherein said matrixing agent has a viscosity between 10,000 and 150,000 mPas in a 2% by weight aqueous solution at 20° C.
Claim 4
Dependent Claim
34 words
A drug formulation according to claim 1, comprising from 25 to 70% by weight of said physiologically acceptable salt of tramadol and from 10 to 40% by weight of said pharmaceutically acceptable matrixing agent.
Claim 5
Dependent Claim
28 words
A drug formulation according to claim 1, which contains from 5 to 65% by weight of conventional excipients selected from the group consisting of fillers, lubricants, and glidants.
Claim 6
Dependent Claim
12 words
A drug formulation according to claim 1, further comprising a film coating.
Claim 7
Dependent Claim
13 words
A drug formulation according to claim 5, wherein said film coating comprises methylhydroxypropylcellulose.
Claim 8
Dependent Claim
15 words
A drug formulation according to claim 5, wherein said film coating comprises swellable, water-insoluble poly(meth)acrylate.
Claim 9
Dependent Claim
18 words
A drug formulation according to claim 5, wherein said film coating contains polyethylene glycol, talc and titanium dioxide.
Claim 10
Dependent Claim
97 words
A drug formulation in tablet form with sustained release of an active ingredient, said drug formulation consisting of from 10 to 85% by weight of non-moisture sensitive, physiologically acceptable tramadol hydrochloride as said active ingredient; from 10 to 40% by weight of at least one pharmaceutically acceptable matrixing agent selected from the group consisting of methylhydroxypropylcelluloses, hydroxyethylcelluloses and hydroxypropylcelluloses having a viscosity between 3,000 and 150,000 mPas in a 2% by weight aqueous solution at 20° C., and from 0 to 80% by weight of conventional excipients selected from the group consisting of fillers, lubricants, and glidants.
Claim 11
Dependent Claim
97 words
A drug formulation in tablet form with sustained release of an active ingredient, said drug formulation consisting of from 10 to 85% by weight of non-moisture sensitive, physiologically acceptable tramadol hydrochloride as said active ingredient; from 10 to 40% by weight of at least one pharmaceutically acceptable matrixing agent selected from the group consisting of methylhydroxypropylcelluloses, hydroxyethylcelluloses and hydroxypropylcelluloses having a viscosity between 3,000 and 150,000 mPas in a 2% by weight aqueous solution at 20° C., and from 0 to 80% by weight of conventional excipients selected from the group consisting of fillers, lubricants, and glidants.
References Cited (Backward Citations)
US4389393A
Cited
US4389393B1
Cited
EP0147780A2
Cited
US4968508A
Cited
US5132116A
Cited
US5073379A
Cited
US5126145A
Cited
US5268181A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-02-11 | 2000-08-12 | 2001-02-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-02-11 | 2004-08-12 | 2005-02-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-02-11 | 2008-08-12 | 2009-02-11 | $7700.00 | Window Closed / Lapsed |